Detalhe da pesquisa
1.
A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.
J Biol Chem
; 293(24): 9326-9334, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29678878
2.
Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency.
J Biol Chem
; 289(20): 14392-8, 2014 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24692552
3.
Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones.
Acta Crystallogr D Biol Crystallogr
; 69(Pt 6): 1124-37, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23695257
4.
Selection of single domain binding proteins by covalent DNA display.
Protein Eng Des Sel
; 20(2): 57-68, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17242027
5.
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.
MAbs
; 8(1): 141-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26390837
6.
A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.
Mol Cancer Ther
; 13(8): 2030-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24994770
7.
Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain.
MAbs
; 4(4): 497-508, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22653218
8.
A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties.
J Biol Chem
; 282(5): 3196-204, 2007 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-17130124
9.
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
Int J Cancer
; 116(2): 304-13, 2005 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15800913